Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aceragen Inc ACGN

Healthcare Biotechnology
Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and... see more

Recent & Breaking News (NDAQ:ACGN)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Juno Therapeutics, Inc. to Celgene Corp. is Fair to Shareholders

Business Wire January 22, 2018

BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases

GlobeNewswire January 22, 2018

Idera Pharmaceuticals Provides 2018 Update and Outlook

GlobeNewswire January 5, 2018

35 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  November 29, 2017

U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma

GlobeNewswire November 29, 2017

Analysis: Positioning to Benefit within Kirby, AmerisourceBergen, Celgene, Sabre, Noble Energy, and Idera Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire November 28, 2017

Idera to Present at the 29th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 27, 2017

Biotechnology and Oncology Markets Have Positive Projections

PR Newswire November 17, 2017

Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)

GlobeNewswire November 9, 2017

Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2017

Mid-Afternoon Market Update: Buffalo Wild Wings Rises On Upbeat Earnings; Atossa Genetics Shares Plummet

Benzinga.com  October 26, 2017

Mid-Day Market Update: Essendant Drops After Q3 Results; Achieve Life Sciences Shares Climb

Benzinga.com  October 26, 2017

Mid-Morning Market Update: Markets Open Higher; Twitter Beats Q3 Estimates

Benzinga.com  October 26, 2017

Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

GlobeNewswire October 26, 2017

Idera Pharmaceuticals Provides Corporate Governance Update

GlobeNewswire October 24, 2017

Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire October 24, 2017

16 Biggest Mid-Day Gainers For Thursday

Benzinga.com  October 5, 2017

Stock Performance Review on Biotech Industry -- Galena Biopharma, Idera Pharma, Ignyta, and Jaguar Health

PR Newswire September 18, 2017

18 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  September 11, 2017

Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy

PR Newswire September 10, 2017